Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
After finishing at $17.48 in the prior trading day, Wave Life Sciences Ltd (NASDAQ: WVE) closed at $18.25, up 4.41%. In other words, the price has increased by $4.41 from its previous closing price. On the day, 1.86 million shares were traded. WVE stock price reached its highest trading level at $18.5 during the session, while it also had its lowest trading level at $17.49.
Ratios:
Our goal is to gain a better understanding of WVE by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.51 and its Current Ratio is at 2.51. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In the most recent recommendation for this company, Wedbush on December 12, 2025, Reiterated its Outperform rating but revised its target price to $33 from $20 previously.
On December 09, 2025, RBC Capital Mkts Upgraded its rating to Outperform which previously was Sector Perform but kept the price unchanged to $27.
On October 20, 2025, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $18.Wells Fargo initiated its Overweight rating on October 20, 2025, with a $18 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 11 ’25 when GSK plc bought 1,470,000 shares for $19.00 per share. The transaction valued at 27,930,000 led to the insider holds 18,245,691 shares of the business.
Rawcliffe Adrian sold 42,000 shares of WVE for $630,000 on Dec 08 ’25. The Director now owns 12,700 shares after completing the transaction at $15.00 per share. On Dec 08 ’25, another insider, Wagner Heidi L, who serves as the Director of the company, sold 14,000 shares for $13.50 each. As a result, the insider received 189,000 and left with 44,930 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, WVE now has a Market Capitalization of 3390118144 and an Enterprise Value of 2882495488. For the stock, the TTM Price-to-Sale (P/S) ratio is 30.57 while its Price-to-Book (P/B) ratio in mrq is 23.49. Its current Enterprise Value per Revenue stands at 26.389 whereas that against EBITDA is -21.764.
Stock Price History:
The Beta on a monthly basis for WVE is -1.72, which has changed by 0.41472864 over the last 52 weeks, in comparison to a change of 0.16098404 over the same period for the S&P500. Over the past 52 weeks, WVE has reached a high of $21.73, while it has fallen to a 52-week low of $5.28. The 50-Day Moving Average of the stock is 80.31%, while the 200-Day Moving Average is calculated to be 122.08%.
Shares Statistics:
The stock has traded on average 6.27M shares per day over the past 3-months and 5704150 shares per day over the last 10 days, according to various share statistics. A total of 160.29M shares are outstanding, with a floating share count of 147.79M. Insiders hold about 19.24% of the company’s shares, while institutions hold 75.35% stake in the company. Shares short for WVE as of 1765756800 were 14691352 with a Short Ratio of 2.34, compared to 1763078400 on 15407887. Therefore, it implies a Short% of Shares Outstanding of 14691352 and a Short% of Float of 10.190000000000001.
Earnings Estimates
. The current assessment of Wave Life Sciences Ltd (WVE) involves the perspectives of 12.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.32, with high estimates of -$0.29 and low estimates of -$0.39.
Analysts are recommending an EPS of between -$1.02 and -$1.27 for the fiscal current year, implying an average EPS of -$1.18. EPS for the following year is -$1.21, with 12.0 analysts recommending between -$0.65 and -$1.62.
Revenue Estimates
15 analysts predict $17.12M in revenue for. The current quarter. It ranges from a high estimate of $47M to a low estimate of $7.61M. As of. The current estimate, Wave Life Sciences Ltd’s year-ago sales were $83.75M
A total of 15 analysts have provided revenue estimates for WVE’s current fiscal year. The highest revenue estimate was $72.5M, while the lowest revenue estimate was $33.09M, resulting in an average revenue estimate of $42.9M. In the same quarter a year ago, actual revenue was $108.3M
